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Abstract The spontaneous development of juvenile-
onset, ovarian granulosa cell (GC) tumors in the SWR/Bm
(SWR) inbred mouse strain is a model for juvenile-type GC
tumors that appear in infants and young girls. GC tumor
susceptibility is supported by multiple Granulosa cell
tumor (Gct) loci, but the Gct1 locus on Chr 4 derived from
SWR strain background is fundamental for GC tumor
development and uniquely responsive to the androgenic
precursor dehydroepiandrosterone (DHEA). To resolve the
location of Gct1 independently from other susceptibility
loci, Gct1 was isolated in a congenic strain that replaces the
distal segment of Chr 4 in SWR mice with a 47 9 106-bp
genomic segment from the Castaneus/Ei (CAST) strain.
SWR females homozygous for the CAST donor segment
were confirmed to be resistant to DHEA- and testosterone-
induced GC tumorigenesis, indicating successful exchange
of CAST alleles (Gct1CA) for SWR alleles (Gct1SW) at this
tumor susceptibility locus. A series of nested, overlapping,
congenic sublines was created to fine-map Gct1 based on
GC tumor susceptibility under the influence of pubertal
DHEA treatment. Twelve informative lines have resolved
the Gct1 locus to a 1.31 9 106-bp interval on mouse Chr 4,
a region orthologous to human Chr 1p36.22.
Introduction
Human granulosa cell (GC) tumors are sex cord-stromal
ovarian tumors that are divided into two clinicopathologic
subtypes, adult-type and juvenile-type, based historically
on histology and age at tumor diagnosis. Adult-type GC
tumors are the more common subtype and typically occur
in peri- and postmenopausal women (Bjo¨rkholm and Sil-
fverswa¨rd 1981). Juvenile-type GC tumors can appear in
girls from the time of infancy through adolescence and
present immediate endocrinological and reproductive
complications in addition to malignant potential (Young
et al. 1984). A significant advance in our understanding of
the GC tumorigenic mechanism has come with the intro-
duction of high-throughput sequencing technology and the
identification of a somatic missense mutation (p.C134W) in
the FOXL2 gene that is common and specific for adult-type
GC tumors (Shah et al. 2009; Al-Agha et al. 2011). The
FOXL2 somatic mutation is not strongly associated with
the juvenile subtype, suggesting alternate pathways for
tumorigenic initiation in the juvenile-onset cases. The
development of spontaneous juvenile-onset GC tumors in
females of the SWR/Bm (hereafter SWR) inbred mouse
strain is a model genetic system to identify pathways
leading to juvenile-onset GC tumorigenesis.
The SWR inbred mouse strain and related recombinant
inbred (RI) strains are unique for their heritable and spon-
taneous GC tumor phenotype that affects 1–25 % of the
young female population, depending on strain background
and hormonal stimulation (Beamer et al. 1985). In affected
females, GC tumors develop during a restricted initiation
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window that coincides with puberty (3–4 weeks of age) as
preneoplastic blood-filled follicles that are macroscopically
visible on the ovarian surface (Tennent et al. 1990). By
6–8 weeks of age, the tumors progress to highly vascular-
ized cystic or hemorrhagic masses that are homogeneously
composed of GCs and enclosed within the ovarian bursa
(Beamer et al. 1985; Tennent et al. 1990). Those females
that progress through the pubertal transition unaffected
remain tumor-free, retain fertility with average litter sizes,
and age normally without significant predisposition for the
development of other primary tumors. Those females with
initially benign proliferative tumors have a high risk for
development of malignant disease, with a time course for
progression between 6 and 10 months of age (Beamer et al.
1985; Tennent et al. 1990).
The mouse GC tumors are endocrinologically active,
secreting high levels of estrogen and inhibin (Beamer et al.
1988a; Gocze et al. 1997), similar to their human juvenile
GC tumor counterparts (Young et al. 1984; Sivasankaran
et al. 2009). Spontaneous GC tumor initiation in SWR mice
is also endocrine-sensitive, as demonstrated by tumor
grafting studies that have determined that an intact hypo-
thalamic-pituitary-gonadal axis is required for GC tumor
development (Beamer et al. 1993). In the intact SWR female
mouse, tumor frequency is significantly increased from\1
to C20 % with exogenous androgen supplementation
such as dehydroepiandrosterone (DHEA) and testosterone
(Beamer et al. 1988a, b; Tennent et al. 1993; Dorward et al.
2007). In accordance with the lack of spontaneous GC tumor
development outside the restricted susceptibility window,
postpubertal treatment with these hormones does not stim-
ulate GC tumor initiation (Beamer et al. 1993). Furthermore,
short-term exposure to 17b-estradiol before, but not after,
the appearance of preneoplastic follicular lesions suppresses
GC tumor incidence (Dorward et al. 2007), indicating that
the window of tumor initiation overlaps with that of tumor
prevention in the mouse model. The restricted pubertal
window also suggests that the first wave of maturing folli-
cles have a distinct response to endocrine stimulation rela-
tive to subsequent waves of maturing follicles. A recent
report by Mork et al. (2012) describes temporal differences
in GC specification in the embryonic ovary, which may
contribute to phenotypic differences and developmental
sensitivity of the ovarian follicle responses in SWR tumor-
susceptible females at puberty.
Three previous mapping studies designed to identify
genes associated with GC tumor development in SWR mice
determined that tumor susceptibility is a polygenic trait
involving multiple GC tumor (Gct) susceptibility loci. The
first mapping strategy examined the tumor susceptibility
traits of 14 lines of the SWXJ RI strain set, which carry
different homozygous chromosomal combinations of the
progenitor SWR and SJL/Bm (hereafter SJL) inbred strains
(Svenson et al. 1995; Shultz et al. 1996). Female mice that
retained spontaneous or androgen-induced GC tumor sus-
ceptibility always retained the SWR-derived Gct1 locus on
Chr 4 (Beamer et al. 1988b; Tennent et al. 1993). It was also
determined from the SWXJ strain set that the influence of
DHEA at Gct1 is genetically distinguishable from the action
of testosterone at Gct4 on Chr X, suggesting that Gct1 is a
discrete target for DHEA in female mice that carry the
Gct1SW alleles (Beamer et al. 1988b). An F2 intercross
mapping study using the SWXJ RI parental strains SWR and
SJL confirmed significant linkage of GC tumor suscepti-
bility with SWR alleles at Gct1 on Chr 4, along with Gct2 on
Chr 12, Gct3 on Chr 15, and Gct5 on Chr 9, and confirmed
the modifier influence of SJL alleles at Gct4 on Chr X
(Beamer et al. 1998). To improve genetic resolution, an
N2F1 backcross mapping strategy between the GC tumor–
susceptible SWXJ-9 RI strain and the evolutionarily diver-
gent Mus musculus castaneus (CAST) strain confirmed Gct1
as the fundamental locus for tumor initiation contributed by
SWR and identified three novel autosomal loci, Gct7 on Chr
1, Gct8 on Chr 2, and Gct9 on Chr 13, and two epistatic
interactions between loci on Chrs 17 and 18 and between
loci on Chrs 2 and 10 (Dorward et al. 2005). In this back-
cross, tumor susceptibility alleles were consistently con-
tributed by the Swiss-derived strains (SWR or SJL) that
contribute to the SWXJ-9 genome, with no GC tumor sus-
ceptibility alleles contributed by the CAST strain.
The required contribution of SWR-derived susceptibility
alleles at Gct1 (Gct1SW) to support both spontaneous and
androgen-induced GC tumorigenesis across strain back-
grounds underscored the Gct1SW allele as an essential driver
for this complex and developmentally restricted ovarian
tumor phenotype. To map Gct1 independently from the other
autosomal loci, we constructed a congenic mouse strain that
has a SWR genomic complement with the exception of a
homozygous Chr 4 segment derived from the CAST strain in
the region of Gct1. The congenic line was resistant to GC
tumor development under androgenic influence, and there-
fore it was useful to support a subcongenic mapping strategy
to refine the interval harboring Gct1. In this report, we
present a high-resolution genetic map for the Gct1 ovarian
tumor susceptibility locus and a list of candidate genetic
determinants for early-onset GC tumorigenesis.
Materials and methods
Mouse housing and nutrition
Mice were maintained in the specific-pathogen-free barrier
facility in the Faculty of Medicine at Memorial University
of Newfoundland and housed under a 12:12-h light/dark
cycle. All mice were provided Laboratory Autoclavable
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Rodent Diet 5010 food (27.5 % protein, 13.5 % fat, 59 %
carbohydrate; PMI Nutrition International, Richmond, IN,
USA) and autoclaved water ad libitum. Females were
weaned at 20–23 days of age and housed in groups of two to
five animals per cage, which were 27.9 cm (L) 9 17.8 cm
(W) 9 12.7 cm (H) with high-profile filtered lids and con-
tained sterilized Bed-O-Cobs corn-cob bedding material
(The Andersons, Maumee, OH, USA). All animal proce-
dures were approved by the Institutional Animal Care
Committee of Memorial University of Newfoundland.
SWR.SJL-X.CAST-4 congenic strain development
SWR.SJL-X5 is a previously reported congenic strain that
carries the Gct1SW alleles on Chr 4 and Gct4 alleles on Chr X
derived from the SJL strain (Beamer et al. 1998; Dorward
et al. 2003). SWR.SJL-X5 female mice exhibit increased
penetrance for spontaneous GC tumor initiation (*20 %)
with the same pubertal initiation timing as SWR females,
without the requirement for exogenous androgen adminis-
tration. A large segment of Chr 4 from the CAST strain was
transferred onto the SWR.SJL-X5 congenic strain background
through ten consecutive backcross generations followed by
brother–sister intercross generations to create the unique
strain SWR.SJL-X.CAST-4T (hereafter Line 4-T). The
CAST homozygous donor segment of Line 4-T spans the
region D4Mit31–D4Mit256, a 47.6 9 106-bp interval that
includes the confidence intervals previously determined for
the Gct1 locus (Beamer et al. 1998; Dorward et al. 2003). The
polymorphic CAST strain was chosen as a donor strain in the
congenic mapping scheme to facilitate high-resolution
genetic mapping of Gct1. The N10 backcross scheme also
replenished the SWR.SJL-X5 genomic background (esti-
mated return of[99 % host genomic material). Established
mating pairs of Line 4-T were confirmed to possess SWR
allelic background at other mapped Gct susceptibility loci on
Chrs 9, 12, and 15 and SJL allelic background at Gct4.
Recombinant subcongenic lines were produced by mating
Line 4-T females with SWR.SJL-X5 males to produce prog-
eny heterozygous for CAST and SWR on Chr 4 between
D4Mit31 and D4Mit256. Subsequent backcrossing to
SWR.SJL-X5 generated N2F1 mice with unique combinations
of the CAST and SWR genomes across the Gct1 locus via
meiotic recombination. Selected recombinants were chosen
as founders for nested and overlapping subcongenic lines that
were fixed to homozygosity through brother–sister matings
prior to phenotype assessment for GC tumor susceptibility.
Phenotyping
Granulosa cell tumor initiation is a spontaneous, low-
penetrance trait in female SWR mice that is sensitive to the
androgenic environment (Beamer et al. 1985). Both DHEA
and testosterone treatments increase trait penetrance in SWR
females and GC tumor–susceptible SWXJ strains with the
expectation for different genetic targets on Chr 4 and Chr X,
respectively (Beamer et al. 1988b). To test the GC tumor
initiation phenotype of Line 4-T females, DHEA or testos-
terone was administered to prepubertal females (age =
20–24 days) in the form of a subcutaneous capsule. DHEA
(5-androsten-3b-ol-17-one) or testosterone (4-androsten-
17b-ol-3-one) (Steraloids Inc., Newport, RI, USA) was
packed into 1.0-cm capsules made from Silastic tubing
(1.98-mm inner diameter 9 3.18-mm outer diameter; Dow
Corning, Midland, MI, USA) capped with glass beads, as
previously described (Beamer et al. 1988a). Capsules were
implanted subcutaneously on the back at the time of weaning
under isoflurane anesthesia (Baxter Corporation, Mississa-
uga, ON, Canada) with postoperative carprofen (5 mg/kg
body weight [bw]) analgesic (Pfizer Canada, Kirkland, QC,
Canada). For phenotypic examination, female mice were
necropsied at 8 weeks of age and ovaries were examined for
GC tumors. At this age, tumors present as unilateral or
bilateral, cystic or solid hemorrhagic masses of 5–10 mm3
that are macroscopically identifiable. Females with either
unilateral or bilateral GC tumors were counted as one
affected animal. Following confirmation of the GC tumor-
resistant phenotype in Line 4-T females, all subcongenic line
females were administered the DHEA capsule treatment to
categorize the lines as tumor-susceptible or tumor-resistant.
Genotyping
Genomic DNA isolated from tail tip biopsy was genotyped
with a series of 22 SSLP markers around Gct1 using a
MasterTaq Kit (5 PRIME Inc., Gaithersburg, MD, USA).
Each PCR reaction contained 7.3 lL of distilled water, 1
lL of 5 9 TaqMaster PCR Enhancer heated to 65 C, 1 lL
of 10 9 Reaction Buffer, 0.2 lL of 10 mM dNTPs
(Invitrogen, Carlsbad, CA, USA), 0.22 lL each of 10 lM
forward and reverse primers (Integrated DNA Technolo-
gies, Coralville, IA, USA), 0.05 lL of Taq DNA poly-
merase, and 1 lL of DNA template. PCR conditions were
as follows: 97 C for 30 s; 39 cycles of 94 C for 15 s,
55 C for 30 s, and 72 C for 30 s; 72 C for 10 min.
Informative markers were determined using the Mouse
Genome Database (Eppig et al. 2012) and included
D4Mit31, D4Mit279, D4Mit70, D4Mit148, D4Mit179,
D4Mit13, D4Mit126, D4Mit160, D4Mit232, D4Mit233,
D4Mit206, D4Mit129, D4Mit49, D4Mit362, D4Mit127,
D4Mit190, D4Mit208, and D4Mit256. PCR-based DNA
markers were also designed in-house around novel SSLPs:
D4sjh19 (5’-GTG GGG AGC ATG TCC TTA AA and
5’-TGG GAG TGT GTA GCA GAG GA), D4sjh10 (5’-GCA
GAA ATG GCA CAG GAG AT and 5’-CCC ACA TTT
GAA ACC ACC TC), D4sjh12 (5’-TTT GGA GAC CAA
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AGA TGA GAC A and 5’-CTT TTC TGG CCT CTG ACC
TG), and D4sjh13 (5’-TCT GGT TTC TAT GCG TGT GC
and 5’-CGG GAT CCA TAT GGT AGT GG). SSLP PCR
products were separated by horizontal electrophoresis in 4 %
MetaPhor agarose slab gels (Lonza, Rockland, ME, USA).
The bands were visualized by ethidium bromide staining and
were photographed for allele scoring purposes.
To facilitate fine mapping of Gct1, additional genetic
polymorphisms between the CAST and SWR genomes were
determined to supplement annotated DNA markers. Primer
sequences were designed around known single nucleotide
polymorphisms (SNPs) annotated in dbSNP (Sherry et al.
2001), or made use of unique SNPs identified during pre-
liminary candidate gene sequencing (Supplementary
Table 1). Because the SWR strain sequence is not publicly
available, annotated SNPs were chosen on the basis of dif-
ferences between CAST alleles and the alleles of other com-
mon inbred strains, particularly Swiss-derived strains that are
phylogenetically related to SWR (Petkov et al. 2004). Each
PCR reaction contained 22.5 lL of AccuprimeTM Pfx Su-
permix, 0.25 lL each of 10 lM forward and reverse primers,
and 2 lL of salt-extracted kidney DNA template. PCR con-
ditions were as follows: 95 C for 5 min; 35 cycles of 95 C
for 15 s, 55 C for 30 s, and 68 C for 45 s; 72 C for 10 min.
The amplicons were sequenced in both directions using a
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA, USA), on a 3730 DNA Analyzer
and aligned with published sequences using Sequencher ver.
4.10.1 (Gene Codes Corporation, Ann Arbor, MI, USA).
Statistical analysis
A sufficient sample size per subcongenic line was deter-
mined to be 50 individual females based on statistical
power calculations using an estimated DHEA-induced GC
tumor incidence of 20 % in susceptible lines relative to a
tumor-resistant phenotype of 0 % (Beamer et al. 1988b).
Type I and Type II error probabilities were set to a = 0.05
and b = 0.20, respectively. The GC tumor incidence of
each subcongenic line was individually compared to the
SWR inbred line incidence using the v2 analysis for pro-
portions, with a chosen significance level of P \ 0.05. All
statistical analyses were performed with GraphPad Prism
ver. 5.00 (GraphPad Software, San Diego, CA, USA).
Results
GC tumor incidence in SWR.SJL-X.CAST-4 founder
congenic and subcongenic lines
Following the construction of the homozygous congenic Line
4-T, female mice were tested for GC tumor susceptibility
under the influence of testosterone or DHEA, as per previous
studies with SWR inbred and SWXJ RI strain females. Nei-
ther DHEA nor testosterone administration in the form of
subcutaneous capsule implants triggered GC tumor develop-
ment in Line 4-T females (Table 1). In direct contrast, SWR
females exhibited a GC tumor incidence of 18 % with DHEA
capsule administration, in keeping with historical incidence
following androgen supplementation in the diet (Table 1;
Beamer et al. 1993). The GC tumor-resistant phenotype of
Line 4-T females provided two key findings in support of the
chosen congenic mapping strategy to resolve Gct1: (1) con-
firmation that the transferred genomic segment from the
CAST strain encompassed the Gct1 locus, such that the
Gct1SW tumor susceptibility alleles were replaced by Gct1CA
resistance alleles, and (2) confirmation that Gct1SW is the
driver for the ovarian GC tumor susceptibility phenotype,
despite the accumulated genetic evidence for multiple genetic
modifiers of susceptibility on Chr X and several autosomes.
Twelve informative SWR.SJL-X.CAST-4 recombinant
subcongenic lines (Lines 4-1 through 4-12), with unique
recombinations of the Gct1SW and Gct1CA alleles across the
Gct1 locus, were successfully derived from the founder
congenic Line 4-T and tested for GC tumor susceptibility
with subcutaneous DHEA-filled capsules. The genotypes of
the individual lines across the Gct1 interval and the phe-
notype results for the groups of females examined for each
line are represented in Fig. 1. Females from Lines 4-7
through 4-12 were GC tumor susceptible compared to
Lines 4-1 through 4-6, which are GC tumor-resistant and
therefore phenocopy Line 4-T. GC tumor incidences of the
individual susceptible Lines 4-7 through 4-12 (18, 11, 19,
18, 27, and 16 %, respectively) were not different from
SWR females treated with the same lot of DHEA (18 %),
while the lines with a resistant phenotype (0 %) were
significantly different (P \ 0.0001). This indicates that the
Line 4-T recombinant subcongenic Lines 4-7 through 4-12
carry the Gct1SW alleles, whereas Lines 4-1 through 4-6
retain the donor Gct1CA tumor-resistance alleles. The
phenotype-driven mapping process refined the Gct1SW
locus to lie between rs27633106 and D4kns1, a
1.31 9 106-bp interval defined by Line 4-10 at the proxi-
mal boundary and Lines 4-5 and 4-6 at the distal boundary.
Of note, Line 4-7 was found to be heterozygous for SWR
and CAST alleles in the region between markers D4Mit70
Table 1 Granulosa cell tumor incidence in SWR and Line 4-T
female mice treated with testosterone or DHEA at puberty
Strain Testosterone DHEA
SWR 21/121 (17 %)a 9/51 (18 %)
Line 4-T 0/50 (0 %) 0/52 (0 %)
a 0.1 % testosterone diet supplement (Beamer et al. 1993)
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and D4Mit179 following fine-genotyping, but this region
did not interfere with the Gct1 boundary determinations.
Short list of candidate genes for the Gct1 tumor
susceptibility locus
The 1.31 9 106-bp Gct1 interval contains 16 unique
annotated genetic determinants, including 10 protein-
coding genes, 2 processed transcripts, 4 noncoding RNA
genes, and 23 pseudogenes (Ensembl Mouse Genome
Browser release 67; NCBI m37 May 2012; Flicek et al.
2012). The majority of the annotated features are located at
the distal end of the Gct1 interval, which is particularly
pseudogene-rich and contains repetitive genetic elements.
Table 2 summarizes the features of the 16 annotated genes
in the Gct1 interval.
Discussion
Granulosa cell tumors of the sex cord-stromal class can
affect women at either end of the reproductive spectrum
and have generally been classified as adult- or juvenile-type
based on age of onset and histology. The latest classification
paradigm incorporates molecular genetic strategies, with the
report of a specific association for a somatic missense
(p.C134W) mutation in the FOXL2 transcription factor in
adult human GC tumors (Schrader et al. 2009; Shah et al.
2009). FOXL2 is a member of the forkhead/hepatocyte
nuclear factor 3 gene family, which is involved in normal
ovarian development and GC differentiation in several
species (Pisarska et al. 2011). The mechanism of the
p.C134W FOXL2 somatic mutation to support adult-type
GC tumorigenesis is under investigation (Benayoun et al.
2010; D’Angelo et al. 2011; L’Hoˆte et al. 2012), but the
curious lack of association of this genetic variant with
juvenile-type GC tumors of the ovary supports the likeli-
hood for an alternate genetic etiology in juvenile cases.
Identification of Gct1 in the SWR mouse model would
provide another avenue of genetic investigation for juvenile-
type GC tumors in human patients that may be dependent or
independent of FOXL2 activity.
Granulosa cell tumorigenesis in the SWR mouse reca-
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Females from the SWR.SJL-
X.CAST congenic sublines 4-7
through 4-12 have significantly
increased GC tumor incidence
compared with individuals from
line 4-T and lines 4-1 through
4-6 (P \ 0.0001). Tumor-
susceptible strains share
common regions of SWR
genetic background between
markers rs27633106 and
D4kns1, for a minimal
1.31 9 106-bp genetic interval
containing Gct1 that is defined
by line 4-10 at the proximal
boundary and lines 4-5 and 4-6
at the distal boundary. Line 4-7
was found to be heterozygous
for SWR and CAST alleles in




region lies outside of the Gct1
interval and does not influence
tumorigenesis. Mb 106-bp
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and genetic investigations for this polygenic ovarian trait
has identified Gct1 on distal mouse Chr 4 as a fundamental
locus for GC tumor initiation during the restricted window
of susceptibility at the pubertal transition. This study
employed a subcongenic mapping strategy to refine the
Gct1 locus using androgen supplementation to increase
trait penetrance. DHEA administration facilitated genetic
mapping of Gct1 and reinforced the extent of steroid hor-
mone influence upon the mechanism of GC tumor initiation
in the mammalian ovary.
Previous mapping studies were unable to resolve the
Gct1 interval to a practical list of candidate genes, despite
strong genetic evidence for the existence of a unique
tumorigenic driver determinant on distal Chr 4 in the SWR
strain. The congenic mapping strategy described herein has
resolved Gct1 to a 1.31 9 106-bp interval, a defined can-
didate gene list, and a congenic strain resource for mech-
anistic studies related to early-onset GC tumorigenesis. The
refinement of Gct1 was aided by the empirical identifica-
tion of novel SSLP- and SNP-based genotyping DNA
markers that are polymorphic between SWR and CAST
strains because the published DNA marker resources had
been exhausted. The 1.31 9 106-bp interval currently
contains annotations for 16 known protein-coding genes,
known and novel processed transcripts, noncoding RNA
genes, and 23 annotated pseudogenes. Until Gct1 is iden-
tified and validated, all DNA polymorphisms unique to the
SWR strain within the mapped Gct1 interval are under
consideration as causative of the trait. In SWR mice, the
DHEA-responsive nature of the Gct1 locus is an opportu-
nity to further interrogate the list of candidate genes;
however, no candidate genes within the narrowed interval
are currently known to be responsive to DHEA in terms of
gene expression or ligand-binding activities.
Four characterized protein-coding genes within the Gct1
interval are conserved between mouse and human based on
current genome annotations: Vps13d, Tnfrsf8, Tnfrsf1b, and
Dhrs3. Given our hypothesis that mouse GC tumor-suscep-
tibility candidates will provide translational information for
juvenile-onset GC tumors of the ovary in young female
patients, these genes have been given priority for further
investigation based on sequence and expression analysis. A
comparison of fully differentiated tissue-specific expression
patterns is available for these four candidates based on the
Gene Expression Atlas initiative (Su et al. 2004) accessed
through the BioGPS web portal (www.biogps.gnf.org; Wu
et al. 2009). The four genes show evidence of expression in
both the mouse and the human ovary, in agreement with our
qualitative transcript assessment in the SWR mouse ovary
(data not shown). Since it is our goal to identify the
Table 2 Identity and features of the genetic determinants within the Gct1 interval
Genea Description Gene ontology Location






(SDR family) member 3
Oxidoreductase activity 144,482,730 ? PC 8
Vps13d Vacuolar protein sorting 13 D (yeast) ND 144,562,529 - PC 10
Tnfrsf1b Tumor necrosis factor receptor
superfamily, member 1b
TNF receptor 144,803,366 - PC 2
Tnfrsf8 Tumor necrosis factor receptor
superfamily, member 8
TNF receptor 144,857,040 - PC 2
Gm13227 Predicted gene 13227 ND 145,000,148 ? NPT 2
Gm13225 Predicted gene 13225 ND 145,100,662 ? PC 4
Gm13242 Predicted gene 13242 ND 145,104,787 ? PC 3
Gm13212 Predicted gene 13212 ND 145,175,069 ? PC 3
Gm17609 Predicted gene 17609 ND 145,191,866 - LINC 1
Gm13236 Predicted gene 13236 ND 145,352,832 ? LINC 1
AL929465.1 – ND 145,454,975 ? NMI 1
Gm13235 Predicted gene 13235 ND 145,458,697 ? PC 2
Gm13248 Predicted gene 13248 ND 145,539,879 - PC 2
1700095A21Rik RIKEN cDNA 1700095A21Rik gene ND 145,651,166 ? AS 1
Gm13247 Predicted gene 13247 ND 145,658,647 - PC 2
Gm17565 Predicted gene 17565 ND 145,686,275 ? LINC 1
AS novel antisense, LINC lincRNA, PC protein coding, ND not determined, NMI novel miRNA, NPT novel processed transcript, ? forward, -
reverse
a Excluded from this list are the 23 known pseudogenes present within the Gct1 interval
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mechanism of GC tumorigenesis in the SWR mouse, these
genes are of significant interest, given their reported bio-
logical functions and relevant expression patterns.
Vps13d is a complex mouse gene with multiple isoforms.
It has not been well characterized but is a member of the
vacuolar-protein-sorting 13 (VPS13) gene family that is
conserved across several species. In yeast, VPS proteins are
involved in the trafficking of membrane proteins between
the trans-Golgi network and the prevacuolar compartment.
Velayos-Baeza et al. (2004) predicted through in silico
analyses that the human VPS13D protein may have two
putative domains: a ubiquitin-associated domain that confers
protein target specificity in the ubiquitination pathway
(Hofmann and Bucher 1996), and a ricin-B-lectin domain,
which is present in many carbohydrate-recognition proteins
and can bind simple sugars (Hazes 1996). It is hypothesized
that if these putative domains are present, VPS13D is
involved in the trafficking of ubiquitin-tagged proteins and/
or carbohydrates (Velayos-Baeza et al. 2004).
Tnfrsf8 is a member of the TNF-receptor superfamily
which is expressed mainly in activated cells of the immune
system (Berro et al. 2004). Tnfrsf8 signaling can have
proliferative and survival or antiproliferative and apoptotic
effects depending on the cellular and stimulatory context
(Gruss et al. 1994; Mir et al. 2000). Serum Tnfrsf8 levels
have been found to be increased in patients with autoim-
mune diseases and those infected with hepatitis B, hepatitis
C, Epstein-Barr, and HIV, and Tnfrsf8 expression is
upregulated in hematological malignancies, including
Hodgkin’s and non-Hodgkin’s lymphomas (reviewed by
Oflazoglu et al. 2009).
Tnfrsf1b, a member of the TNF-receptor superfamily, is a
type I transmembrane receptor that binds tumor necrosis
factor alpha (TNFa). Tnfrsf1b contains a short, C-terminal
intracellular region that is involved in binding TNF receptor
associated factor 2 (TRAF2). TRAF2 binding triggers the
recruitment of cellular inhibitor of apoptosis 1 (c-IAP1) and
c-IAP2, which leads to Jun N-terminal kinase and NF-jB
activation (reviewed by Carpentier et al. 2004). When sig-
naling through Tnfrsf1b, TNFa negatively regulates ovarian
folliculogenesis, as Tnfrsf1b-null mice had increased num-
bers of growing follicles compared to strain controls
(Greenfeld et al. 2007); however, it is not clear if this is
through an alteration of follicle growth rate, reduced follic-
ular atresia, or some other mechanism. In humans, the
p.M196R TNFRSF1B variant has been associated with hy-
perandrogenism and polycystic ovary syndrome in women
(Peral et al. 2002). An established role for Tnfrsf1b in the
ovary and its activation of pathways resulting in proliferation
and cell survival strengthen its standing as a candidate for
Gct1 and the existence of a unique allele in the SWR strain.
The Dhrs3 gene encodes a short-chain dehydrogenase/
reductase that is induced by retinoic acid and reduces
all-trans-retinal, a storage form of vitamin A, in a process
necessary for photoreception (Haeseleer et al. 1998;
Cerignoli et al. 2002). Dhrs3 is expressed in multiple dif-
ferentiated tissues besides the retina, and DHRS3 expres-
sion has been found to be upregulated in human papillary
thyroid carcinomas, although it is negatively correlated with
subsequent lymph node metastasis (Oler et al. 2008). Dhrs3
was found to be a downstream target of bone morphogenic
protein 2, a TGFb family member expressed in GCs of antral
follicles that regulates follicle-stimulating hormone receptor
and aromatase expression and the prevention of premature
follicle luteinization (Bachner et al. 1998; Shi et al. 2011).
Dhrs3 is under investigation as a candidate for shared
identity with Gct1, as we continue to examine all candidate
genes in the interval using a whole-locus customized
sequencing approach, gene expression analysis, and in vivo
functional strategies in GC tumor-susceptible SWR mice.
We anticipate that the combination of strategies will reveal
unique SWR polymorphisms, the endocrine-sensitive
tumorigenic mechanism, and an explanation for trait sensi-
tivity to DHEA.
The SWR mouse model for GC tumorigenesis is a
unique and realistic model for genetically complex and
stochastic cancer risk and a well-described model for
juvenile GC tumors in pediatric patients. Pursuit of GC
tumor susceptibility genes in the mouse will provide spe-
cific candidates for further investigation in juvenile GC
tumor cases to elucidate a genetic etiology for this unique
ovarian tumor class. The interval for Gct1 is orthologous to
human Chr 1p36.22, a region that has been implicated in a
number of disorders through genome-wide association and
cytogenetic studies. Kreisel et al. (2011) identified copy
number alterations at Chr 1p36.22 in a subset of diffuse
large B-cell lymphomas, an aggressive form of non-
Hodgkin’s lymphoma. Human Chr 1p36.22 has also been
identified as a region frequently lost in human hepatocel-
lular carcinoma (Nishimura et al. 2006) and is a suscepti-
bility locus for hepatocellular carcinoma in patients with
hepatitis B virus infection (Zhang et al. 2010). Deletions at
human Chr 1p36.22 are also frequent in infiltrating ductal
carcinoma of the breast (Hawthorn et al. 2010) and pre-
menopausal breast cancers (Varma et al. 2005). Loss of
heterozygosity at the Chr 1p36.2 region is associated with
neuroblastoma (Mora et al. 2000), and multiple putative
tumor suppressor genes within the same region have been
identified (Krona et al. 2004; Liu et al. 2011). Despite these
associations, Chr 1p36.22 has not been linked with adult-
or juvenile-type GC tumor susceptibility, although the
rarity of cases in the human population has precluded
genetic linkage studies. The identification of Gct1 in the
mouse model will permit cross-examination of the role
for this ovarian GC tumor susceptibility allele in other
malignancies genetically associated with Chr 1p36.22.
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